AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (1.5 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Shuyi Hu1,*, Zipeng Wu1,*, Yingying Dai2,*, Xinhong Shi1, Qin Hu1, Caolu Liu2, Yifei Zhu1, Ruofan Yu1, Jingwen Li1, Ying Liu1, Tianyi Liu2, Lin Lu2, Chengyun Yao2, Bo Shen1, Meiqi Shi1, Cheng Chen2,3 ( ), Xiaohua Wang1 ( ), Guoren Zhou1 ( )
Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
Peking University Cancer Hospital (Inner Mongolia Campus), Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot 010020, China

*These authors contributed equally to this work.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-22-12-1544_ESM1.docx (19.2 KB)
cbm-22-12-1544_ESM2.docx (956.5 KB)
cbm-22-12-1544_ESM4.docx (35.3 KB)
cbm-22-12-1544_ESM5.docx (28.9 KB)
cbm-22-12-1544_ESM6.docx (29.1 KB)
cbm-22-12-1544_ESM7.docx (19.7 KB)
Image
cbm-22-12-1544_ESM3.jpg

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 22 Issue 12,
December 2025
Pages 1544-1552
DOI: 10.20892/j.issn.2095-3941.2025.0393

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Hu S, Wu Z, Dai Y, et al. Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy. Cancer Biology & Medicine, 2025, 22(12): 1544-1552. https://doi.org/10.20892/j.issn.2095-3941.2025.0393

71

Views

1

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 28 August 2025
Accepted: 03 November 2025
Published: 10 December 2025
©2025 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License